Keywords: development, b-ms, pargluva, discontinued, drug, major, bristol-myers
Development of B-MS' Pargluva discontinued
Article | 29 May 2006
US drug major Bristol-Myers Squibb has discontinued the development of Pargluva (muraglitazar), its dual alpha-gamma peroxisome proliferator-activated receptor agonist in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
